MCID: MLG068
MIFTS: 59

Malignant Glioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Glioma

MalaCards integrated aliases for Malignant Glioma:

Name: Malignant Glioma 38 12 52 14 69
Glioma 42 69
Malignant Neuroglial Tumor 12
Glioma, Malignant 12
Glial Cell Tumor 12
Neuroglial Tumor 12

Classifications:



Summaries for Malignant Glioma

Disease Ontology : 12 A cell type cancer that has material basis in glial cells and is located in brain or located in spine.

MalaCards based summary : Malignant Glioma, also known as glioma, is related to lymphopenia and astrocytoma. An important gene associated with Malignant Glioma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioma and Signaling by GPCR. The drugs Gliadel Wafer and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Related Diseases for Malignant Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
id Related Disease Score Top Affiliating Genes
1 lymphopenia 30.9 EGFR GFAP PTEN TP53
2 astrocytoma 11.2
3 acquired hemangioma 11.1 EGFR MMP2 MMP9
4 glioma 11.1
5 pancoast tumor 11.1 GFAP TP53
6 facial arteriovenous malformation 11.1 MMP2 MMP9
7 pediatric infratentorial ependymoma 11.0 EGFR TP53
8 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 11.0 EGFR GFAP TP53
9 adenosine monophosphate deaminase 1 deficiency 11.0 MMP2 MMP9 VEGFA
10 colon squamous cell carcinoma 11.0 CDKN2A MMP2 MMP9
11 cervical adenoid cystic carcinoma 11.0 CDKN2A TP53
12 brain stem astrocytic neoplasm 11.0 GFAP TP53
13 oligomeganephronic renal hypoplasia 11.0 MMP2 MMP9 VEGFA
14 multiple carboxylase deficiency 11.0 CDKN2A EGFR TP53
15 rectum squamous cell carcinoma 11.0 CDKN2A MGMT TP53
16 middle ear squamous cell carcinoma 11.0 CDKN2A EGFR TP53
17 rectum kaposi's sarcoma 11.0 EGFR PTEN TP53
18 schwannoma of jugular foramen 11.0 GFAP MGMT TP53
19 secondary hyperparathyroidism of renal origin 11.0 CDKN2A EGFR TP53
20 omphalomesenteric cyst 11.0 GFAP MGMT
21 distal monosomy 7q36 11.0 EGFR TP53 VEGFA
22 molluscum contagiosum 11.0 CDKN2A EGFR TP53
23 xanthogranulomatous cholecystitis 11.0 CASP3 MMP2 MMP9
24 gliofibroma 11.0 GFAP MGMT TP53
25 esophagus squamous cell carcinoma 11.0 CDKN2A PTEN TP53
26 ductal carcinoma in situ 11.0 CDKN2A EGFR TP53
27 familial short qt syndrome 11.0 MMP2 MMP9
28 cecum adenocarcinoma 11.0 CDKN2A EGFR TP53
29 tumor of exocrine pancreas 11.0 CDKN2A EGFR VEGFA
30 prostate adenoid cystic carcinoma 11.0 GFAP MGMT TP53
31 tenosynovitis of foot and ankle 11.0 MMP2 TP53 VEGFA
32 plasmodium ovale malaria 11.0 CDKN2A GFAP TP53
33 rnase t2-deficient leukoencephalopathy 11.0 CDK4 TP53
34 spindle epithelial tumor with thymus-like differentiation tumor 11.0 CDKN2A EGFR MMP2 MMP9
35 dental caries 11.0 MMP2 TP53 VEGFA
36 anaerobic pneumonia 11.0 CDKN2A EGFR TP53
37 nasal cavity disease 11.0 MMP2 TP53 VEGFA
38 secondary pulmonary hemosiderosis 10.9 CDK4 CDKN2A TP53
39 embryonal rhabdomyosarcoma 10.9 CDKN2A MGMT TP53
40 fasciolopsiasis 10.9 CDKN2A MMP2 TP53
41 epidermolysa bullosa simplex with muscular dystrophy 10.9 EGFR GFAP MGMT
42 epidural neoplasm 10.9 CDK4 CDKN2A VEGFA
43 glycogen storage disease due to lactate dehydrogenase deficiency 10.9 CASP8 EGF TP53
44 bannayan-riley-ruvalcaba syndrome 10.9 EGFR PTEN
45 fallopian tube mucinous tumor 10.9 CDKN2A EGFR TP53
46 choriocarcinoma 10.9 CDKN2A TP53 VEGFA
47 pancreatoblastoma 10.9 CDKN2A GFAP TP53
48 pancreatic somatostatinoma 10.9 CDKN2A EGFR TP53
49 pituitary infarct 10.9 MMP9 PTEN VEGFA
50 anaerobic meningitis 10.9 EGFR TNFRSF10B VEGFA

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma

Symptoms & Phenotypes for Malignant Glioma

GenomeRNAi Phenotypes related to Malignant Glioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 TNFRSF10B TNFSF10 TP53 CASP3 CASP8 CDKN2A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 TNFSF10 TP53 CASP3 CASP8 CDKN2A PPME1
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CDK4 EGFR PPME1 PTEN VEGFA
4 Decreased viability with paclitaxel GR00179-A-1 9.26 PTK2 CASP3 EGFR
5 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR

MGI Mouse Phenotypes related to Malignant Glioma:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 TERT TNFSF10 TP53 VEGFA CASP3 CASP8
2 immune system MP:0005387 10.47 VEGFA CASP3 CASP8 CDK4 CDKN2A EGF
3 cardiovascular system MP:0005385 10.45 CASP3 CASP8 CDK4 CDKN2A EGFR GFAP
4 growth/size/body region MP:0005378 10.44 CASP3 CASP8 CDK4 CDKN2A EGF EGFR
5 hematopoietic system MP:0005397 10.43 CASP3 CASP8 CDK4 CDKN2A EGFR IL13RA2
6 mortality/aging MP:0010768 10.42 CASP3 CASP8 CDK4 CDKN2A EGFR GFAP
7 cellular MP:0005384 10.41 KDR MMP9 PTEN PTK2 TERT TP53
8 endocrine/exocrine gland MP:0005379 10.39 CASP3 CASP8 CDK4 CDKN2A EGF EGFR
9 digestive/alimentary MP:0005381 10.37 PTK2 TERT TP53 VEGFA CASP3 CDK4
10 integument MP:0010771 10.3 CASP8 CDK4 CDKN2A EGF EGFR KDR
11 muscle MP:0005369 10.29 VEGFA CASP3 CASP8 CDK4 CDKN2A EGFR
12 nervous system MP:0003631 10.28 CASP3 CASP8 CDK4 CDKN2A EGFR GFAP
13 neoplasm MP:0002006 10.27 CDK4 CDKN2A EGFR MGMT MMP2 MMP9
14 embryo MP:0005380 10.24 EGFR KDR PTEN PTK2 TP53 VEGFA
15 liver/biliary system MP:0005370 10.21 CDKN2A EGFR KDR PTEN PTK2 TNFSF10
16 normal MP:0002873 10.14 EGFR GFAP KDR MMP2 PTEN PTK2
17 reproductive system MP:0005389 10 VEGFA CASP3 CDK4 CDKN2A EGF EGFR
18 respiratory system MP:0005388 10 CASP3 CASP8 CDKN2A EGFR KDR MGMT
19 renal/urinary system MP:0005367 9.92 CASP3 CASP8 CDK4 EGFR MMP9 PTEN
20 pigmentation MP:0001186 9.85 CASP3 CDK4 CDKN2A EGFR PTEN TP53
21 skeleton MP:0005390 9.7 CASP3 CDKN2A EGFR KDR MMP2 MMP9
22 vision/eye MP:0005391 9.4 CASP3 CDK4 CDKN2A EGF EGFR GFAP

Drugs & Therapeutics for Malignant Glioma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 46 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85622-93-1 5394
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
5
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
6
Procarbazine Approved Phase 3,Phase 2 671-16-9 4915
7
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
8
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
9
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
10
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
11
Somatostatin Approved Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
12
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
13
Dalteparin Approved Phase 3 9005-49-6
14
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
15
chloroquine Approved, Vet_approved Phase 3 54-05-7 2719
16
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
17
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
18
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
20
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
21 tannic acid Approved, Nutraceutical Phase 3,Phase 2
22
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262 389
23 Mitolactol Investigational Phase 3 10318-26-0
24 Dermatologic Agents Phase 3,Phase 2,Phase 1
25 Dihematoporphyrin Ether Phase 3,Phase 2
26 Ether Phase 3,Phase 2
27 Photosensitizing Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Hormonal Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3, Phase 1
30 Hormones Phase 2, Phase 3, Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3, Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 1,Phase 2
34 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
35 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
36 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
37 Antibodies Phase 2, Phase 3,Phase 1
38 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
39 Immunoglobulins Phase 2, Phase 3,Phase 1
40 Anesthetics Phase 3,Phase 2,Phase 1
41 Edotreotide Phase 2, Phase 3
42 Gastrointestinal Agents Phase 2, Phase 3, Phase 1
43 Radiopharmaceuticals Phase 2, Phase 3,Phase 1
44 Antimitotic Agents Phase 3,Phase 1,Phase 2
45 Anticoagulants Phase 3,Phase 2
46 calcium heparin Phase 3
47 Fibrinolytic Agents Phase 3
48 Heparin, Low-Molecular-Weight Phase 3
49 Analgesics Phase 3,Phase 2,Phase 1
50 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 451)

id Name Status NCT ID Phase Drugs
1 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
2 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
4 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
5 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
6 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
7 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
8 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
9 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
10 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
11 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
12 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
13 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
14 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
15 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
16 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
17 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
18 3D Ultra Sound for Resection of Brain Tumors Recruiting NCT02150564 Phase 3
19 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
20 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine
21 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
23 Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT01144988 Phase 2 Bevacizumab / Irinotecan
24 Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Unknown status NCT01670890 Phase 2 TMZ;TMZ plus CDDP
25 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
26 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma Unknown status NCT00283543 Phase 2 Gliadel Wafer;Temozolomide
27 Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma Unknown status NCT01235845 Phase 1, Phase 2
28 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
29 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
31 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
32 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
33 Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00906516 Phase 2 Neuradiab in combination with Bevacizumab (Avastin)
34 Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT02139579 Phase 2 Bevacizumab
35 Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma Unknown status NCT00003535 Phase 2 antineoplaston A10;antineoplaston AS2-1
36 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
37 A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660621 Phase 2 Temozolomide and Bevacizumab
38 A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660283 Phase 2 Temozolomide
39 A Phase II Study to Treat Advanced Malignant Glioma Completed NCT00427440 Phase 2 AMG 102 at 20 mg/kg;AMG 102 at 10 mg/kg
40 This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. Completed NCT00032903 Phase 1, Phase 2 Gimatecan® (ST 1481)
41 CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients Completed NCT02575261 Phase 1, Phase 2
42 Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) Completed NCT00953121 Phase 2 bevacizumab and CPT-11 and Carboplatin
43 Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme Completed NCT00919737 Phase 1, Phase 2 NPC-08
44 A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Completed NCT00766467 Phase 2 Armodafinil
45 The Safety and Efficacy of DCA for the Treatment of Brain Cancer Completed NCT00540176 Phase 2 Dichloroacetate (DCA)
46 High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma Completed NCT00283556 Phase 1, Phase 2 Irinotecan (Camptosar, CPT-11)
47 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
48 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Completed NCT01738646 Phase 2 Vorinostat;Bevacizumab
49 An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed NCT01386580 Phase 1, Phase 2 2B3-101;Trastuzumab;2B3-101 60 mg/m2 every 4 weeks;2B3-101 50 mg/m2 every 3 weeks
50 Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) Completed NCT00589875 Phase 2 Valacyclovir

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Cochrane evidence based reviews: glioma

Genetic Tests for Malignant Glioma

Anatomical Context for Malignant Glioma

MalaCards organs/tissues related to Malignant Glioma:

39
Brain, T Cells, Bone, Endothelial, Bone Marrow, Lung, Testes

Publications for Malignant Glioma

Articles related to Malignant Glioma:

(show top 50) (show all 1189)
id Title Authors Year
1
Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. ( 28594449 )
2017
2
DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade. ( 28204824 )
2017
3
Evaluation of rat C6 malignant glioma using spectral computed tomography. ( 28810555 )
2017
4
IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway. ( 28548934 )
2017
5
CCR7 Mediates TGF-I^1-Induced Human Malignant Glioma Invasion, Migration, and Epithelial-Mesenchymal Transition by Activating MMP2/9 Through the Nuclear Factor KappaB Signaling Pathway. ( 28817313 )
2017
6
Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy. ( 28938558 )
2017
7
Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis. ( 28886531 )
2017
8
Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. ( 28650441 )
2017
9
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth. ( 28061453 )
2017
10
Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. ( 28555424 )
2017
11
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. ( 27818200 )
2017
12
Relationship between radiation dose and microbleed formation in patients with malignant glioma. ( 28797254 )
2017
13
Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma. ( 28645200 )
2017
14
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity. ( 28480325 )
2017
15
Wavelength-specific lighted suction instrument for 5-aminolevulinic acid fluorescence-guided resection of deep-seated malignant glioma: technical note. ( 28665248 )
2017
16
Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma. ( 28912488 )
2017
17
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. ( 28488122 )
2017
18
A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma. ( 28781647 )
2017
19
Screening critical genes associated with malignant glioma using bioinformatics analysis. ( 28901452 )
2017
20
Study of antioxidant effects on malignant glioma cells by constructing a tumor-microvascular structure on microchip. ( 28595721 )
2017
21
Cytotoxicity induced by carbon nanotubes in experimental malignant glioma. ( 28860763 )
2017
22
5-Aminolevulinic acid fluorescence guided resection of malignant glioma: Hong Kong experience. ( 28844780 )
2017
23
CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. ( 28534507 )
2017
24
AEG-1/MTDH-activated autophagy enhances human malignant glioma susceptibility to TGF-I^1-triggered epithelial-mesenchymal transition. ( 26909607 )
2016
25
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. ( 26945581 )
2016
26
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. ( 27576783 )
2016
27
TRPM7 channel inhibition mediates midazolam-induced proliferation loss in human malignant glioma. ( 27629139 )
2016
28
The potential roles of dopamine in malignant glioma. ( 27995487 )
2016
29
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. ( 26739692 )
2016
30
Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. ( 27576872 )
2016
31
MicroRNA-203 Modulates the Radiation Sensitivity of Human Malignant Glioma Cells. ( 26678661 )
2016
32
Integrin I+VI^3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. ( 27487141 )
2016
33
Identification of two distinct mesenchymal stromal cell populations in human malignant glioma. ( 27757723 )
2016
34
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. ( 27920506 )
2016
35
Malignant glioma with primitive neuroectodermal tumor-like component (MG-PNET): novel microarray findings in a pediatric patient. ( 27781423 )
2016
36
c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma. ( 27602752 )
2016
37
Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. ( 27178315 )
2016
38
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. ( 27734112 )
2016
39
High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. ( 26998166 )
2016
40
Fluorescence-Guided Resection of Malignant Glioma with 5-ALA. ( 27429612 )
2016
41
Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study. ( 27664151 )
2016
42
Exploring the activity of a polyazine bridged Ru(ii)-Pt(ii) supramolecule in F98 rat malignant glioma cells. ( 27901157 )
2016
43
Targeting immune checkpoints in malignant glioma. ( 27756892 )
2016
44
WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients. ( 27370540 )
2016
45
Regulatory landscape and clinical implication of MBD3 in human malignant glioma. ( 27835581 )
2016
46
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. ( 27188199 )
2016
47
Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. ( 26885285 )
2016
48
Akt and I^-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. ( 27423571 )
2016
49
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers. ( 27452129 )
2016
50
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. ( 27192459 )
2016

Variations for Malignant Glioma

Copy number variations for Malignant Glioma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for Malignant Glioma

Search GEO for disease gene expression data for Malignant Glioma.

Pathways for Malignant Glioma

Pathways related to Malignant Glioma according to KEGG:

37
id Name Kegg Source Accession
1 Glioma hsa05214

Pathways related to Malignant Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.25 CASP3 CASP8 CDK4 EGF EGFR GFAP
2
Show member pathways
13.89 CASP3 CASP8 CDKN2A EGF EGFR KDR
3
Show member pathways
13.82 CASP3 CASP8 CDK4 CDKN2A EGF EGFR
4
Show member pathways
13.8 CDK4 CDKN2A EGF EGFR KDR MMP2
5
Show member pathways
13.74 CASP3 CASP8 EGF EGFR IL13RA2 KDR
6
Show member pathways
13.57 CDK4 EGF EGFR KDR MMP2 MMP9
7
Show member pathways
13.49 CASP3 EGF EGFR KDR MMP2 MMP9
8
Show member pathways
13.49 CASP3 EGF EGFR IL13RA2 KDR PTEN
9
Show member pathways
13.45 CASP3 EGF EGFR IL13RA2 MMP2 MMP9
10
Show member pathways
13.37 CASP3 CASP8 EGF EGFR IL13RA2 KDR
11
Show member pathways
13.13 EGF EGFR KDR PTEN PTK2 TP53
12
Show member pathways
13.06 CASP3 CASP8 KDR PTK2 TP53 VEGFA
13
Show member pathways
12.97 EGF EGFR KDR PTEN PTK2 VEGFA
14
Show member pathways
12.97 CASP3 CASP8 MMP9 TNFRSF10B TNFSF10 TP53
15
Show member pathways
12.9 CASP3 CASP8 CDKN2A TNFRSF10B TNFSF10 TP53
16
Show member pathways
12.88 CASP3 CASP8 CDK4 TNFRSF10B TNFSF10 TP53
17
Show member pathways
12.85 CASP3 PTEN PTK2 TP53 VEGFA
18 12.78 CASP3 CASP8 EGF EGFR TP53
19
Show member pathways
12.74 KDR MMP2 MMP9 PTK2 VEGFA
20
Show member pathways
12.71 CASP3 CASP8 KDR TNFRSF10B TNFSF10 VEGFA
21
Show member pathways
12.68 KDR MMP2 MMP9 PTK2 VEGFA
22 12.62 CASP3 CDKN2A EGFR MMP9 PTEN TP53
23
Show member pathways
12.6 CASP3 CASP8 EGF EGFR PTK2 TP53
24
Show member pathways
12.6 CASP3 CDK4 CDKN2A EGF EGFR KDR
25
Show member pathways
12.55 CASP3 CASP8 EGFR KDR PTK2 TP53
26
Show member pathways
12.54 CASP3 CASP8 EGFR KDR MMP2 PTEN
27 12.53 CASP3 CASP8 CDK4 EGF EGFR KDR
28
Show member pathways
12.49 CASP3 EGF EGFR KDR VEGFA
29
Show member pathways
12.46 EGF EGFR KDR PTK2 VEGFA
30
Show member pathways
12.42 CASP3 CASP8 CDK4 CDKN2A PTEN TNFRSF10B
31 12.39 CASP3 CASP8 CDK4 CDKN2A TP53
32
Show member pathways
12.37 EGF EGFR PTK2 TP53
33
Show member pathways
12.36 CASP3 CASP8 TNFRSF10B TNFSF10
34
Show member pathways
12.35 CASP3 CDK4 EGFR KDR PTEN PTK2
35
Show member pathways
12.33 EGFR KDR PTEN PTK2 VEGFA
36 12.31 CASP3 CASP8 TNFRSF10B TNFSF10
37
Show member pathways
12.28 CASP3 CASP8 CDK4 PTEN TNFRSF10B TNFSF10
38 12.26 EGF EGFR PTEN PTK2
39 12.23 CASP3 EGFR KDR MMP2 MMP9 PTK2
40
Show member pathways
12.19 EGF EGFR MMP2 PTEN
41 12.19 CASP3 EGF EGFR MMP2 MMP9 TP53
42 12.18 EGF EGFR KDR PTK2
43 12.18 EGFR MMP2 PTEN TNFRSF10B TP53
44 12.18 CDK4 CDKN2A MGMT PTEN TP53
45 12.18 KDR MMP2 MMP9 PTK2 TP53 VEGFA
46
Show member pathways
12.16 EGF EGFR PTEN TNFSF10
47 12.15 EGF KDR TERT VEGFA
48 12.15 CDKN2A KDR MMP2 TP53 VEGFA
49 12.14 CASP3 CASP8 CDK4 EGFR PTEN TP53
50
Show member pathways
12.13 CASP3 CASP8 EGFR TP53

GO Terms for Malignant Glioma

Cellular components related to Malignant Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.26 CASP3 CASP8 EGFR KDR
2 death-inducing signaling complex GO:0031264 8.62 CASP3 CASP8

Biological processes related to Malignant Glioma according to GeneCards Suite gene sharing:

(show all 41)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.98 CDK4 EGFR PTK2 TNFRSF10B
2 peptidyl-tyrosine phosphorylation GO:0018108 9.93 EGF EGFR KDR PTK2
3 positive regulation of cell migration GO:0030335 9.91 EGFR KDR MMP9 PTK2 VEGFA
4 positive regulation of cell proliferation GO:0008284 9.91 CDK4 EGF EGFR KDR PTEN PTK2
5 response to organic cyclic compound GO:0014070 9.9 CASP3 EGFR MGMT PTEN
6 phosphatidylinositol-mediated signaling GO:0048015 9.88 EGF EGFR PTEN TP53
7 cellular response to hypoxia GO:0071456 9.87 PTEN TERT TP53 VEGFA
8 cellular response to mechanical stimulus GO:0071260 9.86 CASP8 EGFR TNFRSF10B
9 cellular response to organic cyclic compound GO:0071407 9.85 CASP3 CASP8 MGMT
10 response to estradiol GO:0032355 9.85 CASP3 CASP8 EGFR PTEN
11 regulation of protein stability GO:0031647 9.84 CDKN2A PTEN TERT
12 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.84 KDR PTK2 VEGFA
13 extracellular matrix organization GO:0030198 9.83 KDR MMP9 PTK2
14 positive regulation of MAP kinase activity GO:0043406 9.83 EGF EGFR VEGFA
15 positive regulation of protein phosphorylation GO:0001934 9.83 EGFR KDR MMP9 PTK2 VEGFA
16 vasculogenesis GO:0001570 9.82 KDR PTK2 VEGFA
17 epidermal growth factor receptor signaling pathway GO:0007173 9.82 EGF EGFR PTK2
18 learning or memory GO:0007611 9.81 CASP3 EGFR PTEN
19 peptidyl-tyrosine autophosphorylation GO:0038083 9.8 EGFR KDR PTK2
20 execution phase of apoptosis GO:0097194 9.78 CASP3 CASP8 PTK2
21 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.77 CASP8 TNFRSF10B TNFSF10
22 response to antibiotic GO:0046677 9.76 CASP3 CASP8 TP53
23 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.73 MMP9 TNFSF10 TP53
24 angiogenesis GO:0001525 9.73 EGF KDR MMP2 PTEN PTK2 VEGFA
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 MMP2 MMP9 TERT
26 positive regulation of apoptotic process GO:0043065 9.7 CASP3 CDK4 CDKN2A MMP9 PTEN TNFSF10
27 positive regulation of positive chemotaxis GO:0050927 9.68 KDR VEGFA
28 positive regulation of catenin import into nucleus GO:0035413 9.68 EGF EGFR
29 negative regulation of organ growth GO:0046621 9.67 PTEN PTK2
30 macrophage differentiation GO:0030225 9.67 CASP8 MMP9 VEGFA
31 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.65 CASP8 TNFRSF10B TNFSF10
32 response to cobalt ion GO:0032025 9.63 CASP3 CASP8
33 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:2000060 9.63 EGF PTEN PTK2
34 central nervous system neuron axonogenesis GO:0021955 9.62 PTEN PTK2
35 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 KDR VEGFA
36 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.58 CASP8 TNFRSF10B TNFSF10
37 replicative senescence GO:0090399 9.5 CDKN2A TERT TP53
38 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.35 CASP3 CASP8 CDKN2A TNFRSF10B TNFSF10
39 negative regulation of apoptotic process GO:0043066 9.32 CASP3 EGFR KDR MGMT MMP9 PTEN
40 multicellular organism development GO:0007275 10.2 CDK4 EGFR KDR PTK2 TNFRSF10B TP53
41 apoptotic process GO:0006915 10.08 CASP3 CASP8 CDKN2A PTEN TNFRSF10B TNFSF10

Molecular functions related to Malignant Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.46 EGF EGFR KDR PTK2
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.43 CASP3 CDKN2A
3 protein phosphatase binding GO:0019903 9.43 EGFR PPME1 TP53
4 protein kinase binding GO:0019901 9.43 CDKN2A EGFR PPME1 PTEN PTK2 TP53
5 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.37 CASP3 CASP8
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.32 EGFR KDR
7 identical protein binding GO:0042802 9.17 CASP8 EGFR GFAP MMP9 PTEN TP53
8 protein binding GO:0005515 10.33 CASP3 CASP8 CDK4 CDKN2A EGF EGFR

Sources for Malignant Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....